Mar 3 2010
China Medical Technologies,
Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro
diagnostic ("IVD") company, today announced its unaudited financial results
for the third fiscal quarter ended December 31, 2009 ("3Q FY2009"). The
Company's 2009 fiscal year ends on March 31, 2010 ("FY2009").
3Q FY2009 Highlights
-- Revenues decreased by 23.5% year-over-year to RMB172.3 million (US$25.2
million) but increased by 3.8% on a quarter-over-quarter basis.
-- Loss from continuing operations was RMB22.0 million (US$3.2 million).
-- Non-GAAP income from continuing operations, as defined below, decreased
by 61.9% year-over-year to RMB45.6 million (US$6.7 million) but
increased by 158.2% on a quarter-over-quarter basis.
-- Diluted loss from continuing operations per ADS* was RMB0.84 (US$0.12).
-- Non-GAAP diluted earnings from continuing operations per ADS*, as
defined below, decreased by 61.8% year-over-year to RMB1.74 (US$0.25)
but increased by 159.7% on a quarter-over-quarter basis.
-- Net cash flows generated from operations was RMB80.4 million (US$11.8
million).
-- Approximately 390,000 ADSs* were repurchased under the Company's share
repurchase program.
4Q FY2009 Targets
-- Target revenues are expected to be more than RMB175.0 million (US$25.6
million).
-- Target non-GAAP income from continuing operations is expected to be
more than RMB47.0 million (US$6.9 million).
-- Target non-GAAP diluted earnings from continuing operations per ADS* is
expected to be more than RMB1.79 (US$0.26).
* One American Depositary Share ("ADS") = 10 ordinary shares
See "Non-GAAP Measure Disclosures" below, where the impact of certain
items on reported results is discussed.
"We achieved sequential growth in our business in the past quarter,"
commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company.
"Despite the challenges we encountered in the first 9 months of fiscal year
2009, our turnaround has started and will continue, which is demonstrated by
robust growth in our molecular diagnostic business and stabilization in our
immunodiagnostic business in the past quarter. We have witnessed stabilizing
pricing environment for our ECLIA reagent kits and growth of end user demand
for both of our FISH probes and ECLIA reagent kits. Meanwhile, we completed
the trial launch of our SPR system in December 2009 and from January 2010, we
began a formal full scale launch of our SPR system, targeting at least 30 top
tier hospitals each quarter. Besides, we are waiting for SFDA approval for
several new products in both molecular diagnostic business and
immunodiagnostic business in 2010 which will expand our product offering and
strengthen our product portfolio. We expect the Company to experience another
phase of accelerated growth in later quarters."
3Q FY2009 Unaudited Financial Results
The Company reported revenues of RMB172.3 million (US$25.2 million) for 3Q
FY2009, representing a 23.5% decrease from the corresponding period of FY2008
and a 3.8% increase from 2Q FY2009.
The Company's revenues are currently generated from two segments,
molecular diagnostic systems and immunodiagnostic systems. The molecular
diagnostic systems segment includes FISH products and is expected to include
SPR products in 2010 while the immunodiagnostic systems segment consists of
ECLIA products.
Molecular diagnostic system sales for 3Q FY2009 were RMB96.2 million
(US$14.1 million), representing a 2.8% increase from the corresponding period
of FY2008 and a 7.8% increase from 2Q FY2009.
Immunodiagnostic system sales for 3Q FY2009 were RMB76.2 million (US$11.2
million), representing a 42.2% decrease from the corresponding period of
FY2008 and a 0.9% decrease from 2Q FY2009. The year-over-year decrease was
primarily due to the price reduction for ECLIA reagent kits in September 2009.
Gross margin decreased to 63.4% for 3Q FY2009 as compared to 73.9% for the
corresponding period of FY2008 and 65.4% for 2Q FY2009. The decrease in gross
margin was primarily due to the impact of the price reduction on ECLIA reagent
kits.
Research and development expenses were RMB10.7 million (US$1.6 million)
for 3Q FY2009, representing a 29.3% year-over-year increase and a 13.0%
sequential increase. The increase was primarily due to the development of new
FISH probes, SPR-based chips and ECLIA reagent kits.
Sales and marketing expenses were RMB19.1 million (US$2.8 million) for 3Q
FY2009, representing a 63.3% year-over-year increase and a 9.3% sequential
increase. The increase was primarily due to the increase in direct sales
efforts for molecular diagnostic systems.
General and administrative expenses were RMB25.8 million (US$3.8 million)
for 3Q FY2009, representing a 12.6% year-over-year decrease and a 42.7%
sequential decrease. The significant sequential decrease was primarily because
no costs for the independent internal investigation were incurred and the
provision for bad debts was substantially lower in 3Q FY2009.
Amortization of SPR intangible assets was RMB27.3 million (US$4.0 million)
for 3Q FY2009. As the SPR acquisition was completed in December 2008, there
was only one month amortization of SPR intangible assets in the corresponding
period of FY2008.
Interest expense on convertible notes was RMB35.4 million (US$5.2 million)
for 3Q FY2009. The Company's outstanding convertible notes of US$150.0
million and US$276.0 million bear interest at 3.5% and 4.0% per annum,
respectively and will mature in November 2011 and August 2013, respectively.
Due to the adoption of new authoritative guidance governing the accounting for
convertible instruments that can be settled in cash or partially in cash upon
conversion effective on April 1, 2009, the Company recorded additional non-
cash interest expense of RMB7.6 million (US$1.1 million) for the US$150.0
million convertible notes in 3Q FY2009. The Company also made an adjustment
related to these convertible notes for the corresponding period of FY2008 by
increasing non-cash interest expense by RMB7.2 million to adopt this guidance
retrospectively. This new guidance is not applicable to the US$276.0 million
convertible notes.
Interest expense on amortization of convertible notes issuance costs was
RMB4.4 million (US$0.6 million) for 3Q FY2009.
Income tax expense was RMB13.1 million (US$1.9 million) for 3Q FY2009.
The occurrence of income tax expense was primarily because certain expenses of
the Company such as stock compensation expense, amortization of acquired
intangible assets and interest expense on convertible notes were not
deductible for income tax purpose as well as the accrual for withholding
income tax on distributable earnings generated during the quarter in the PRC.
Loss from continuing operations was RMB22.0 million (US$3.2 million) for
3Q FY2009 and net loss was RMB22.0 million (US$3.2 million) for 3Q FY2009.
Non-GAAP income from continuing operations excluding stock compensation
expense, amortization of acquired intangible assets and non-cash interest
expense of convertible notes arising from the adoption of the new guidance
related to convertible instruments that can be settled in cash or partially in
cash upon conversion was RMB45.6 million (US$6.7 million) for 3Q FY2009,
representing a 61.9% decrease from the corresponding period of FY2008 and a
158.2% increase from 2Q FY2009.
Stock compensation expense for 3Q FY2009 was RMB10.2 million (US$1.5
million), of which RMB1.6 million was allocated to research and development
expenses and RMB8.6 million to general and administrative expenses.
Amortization of acquired intangible assets for 3Q FY2009 was RMB49.8
million (US$7.3 million), of which RMB22.4 million was allocated to cost of
revenues and RMB27.4 million to operating expenses.
As of December 31, 2009, the Company's cash and cash equivalents was
RMB829.9 million (US$121.6 million). The decrease in cash and cash
equivalents from the balance at September 30, 2009 was primarily due to the
final payment for the SPR acquisition, the payment of annual cash dividends
and the repurchase of the Company's ADSs. Net cash generated from operating
activities for 3Q FY2009 was RMB80.4 million (US$11.8 million).
As of December 31, 2009, the Company's net accounts receivable was
RMB300.8 million (US$44.1 million), representing a decrease of 5.4% from the
balance at September 30, 2009.
For the convenience of readers, certain RMB amounts have been translated
into U.S. dollars at the rate of RMB6.8259 to US$1.00, the noon buying rate in
New York City for cable transfers of RMB per U.S. dollar as set forth in the
H.10 weekly statistical release of the Federal Reserve Board, as of Thursday,
December 31, 2009. No representation is made that the RMB amounts could have
been or could be converted into U.S. dollars at that rate or at any other
certain rate on December 31, 2009 or at any other dates.
Share Repurchase Program
In September 2009, the Company's board of directors authorized a share
repurchase program, under which the Company may repurchase up to US$30 million
worth of its outstanding ADSs from the open market or in block trades for a
period of one year, commencing on October 1, 2009. As of December 31, 2009,
the Company repurchased about 390,000 ADSs at a cost of approximately US$5.0
million (including transaction costs). The Company will continue to repurchase
issued and outstanding ADSs depending on market conditions, the trading price
of its ADSs and other factors.
Outlook for 4Q FY2009
Although the New Year holiday in January 2010 and the Chinese New Year
holiday in February 2010 reduced about 10% of normal working days in 4Q FY2009,
the Company still expects to achieve sequential growth in its business. In 1Q
FY2010, without the holiday impact, the Company expects to achieve a higher
sequential growth in its business.
The Company estimates the target revenues for 4Q FY2009 to be more than
RMB175.0 million (US$25.6 million).
The Company estimates the target non-GAAP income from continuing
operations for 4Q FY2009 to be more than RMB47.0 million (US$6.9 million).
The Company estimates the target non-GAAP diluted earnings from continuing
operations per ADS for 4Q FY2009 to be more than RMB1.79 (US$0.26).
The above targets are based on the Company's current views on the
operating and marketing conditions, which are subject to change.
SOURCE China Medical Technologies, Inc.